- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
CHMP positive opinion for Keytruda in NSCLC
27 June 2016 • Author: Victoria White, Digital Content Producer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Merck’s Keytruda (pembrolizumab) for the treatment of non-small cell lung cancer (NSCLC).
Specifically, the CHMP has recommended approval of the therapy for the treatment of locally advanced or metastatic NSCLC in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. The positive opinion will now be reviewed by the European Commission for marketing authorisation in the European Union (EU).
Commenting on the news, Dr Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories, said: “This news marks an important step in making Keytruda available for appropriate patients suffering from locally advanced or metastatic non-small cell lung cancer. We are grateful to patients and investigators around the world who participated in these studies and who are helping to advance this important new treatment.”
Positive opinion supported by data from KEYNOTE-010 and KEYNOTE-001
Data supporting the CHMP positive opinion were based on findings from two studies, KEYNOTE-010, a pivotal study assessing overall survival (OS) and KEYNOTE-001, which assessed overall response rates (ORR). KEYNOTE-010 is an open-label, randomised Phase II/III trial assessing OS with two doses of Keytruda (2 mg/kg or 10 mg/kg every three weeks) compared to docetaxel (75 mg/m2 every three weeks), a standard of care chemotherapy, in patients with any level of PD-L1 expression. KEYNOTE-001 is a multicentre, open-label multi-cohort, activity-estimating study evaluating ORR of Keytruda (2 mg/kg or 10 mg/kg every three weeks).
The CHMP recommended approval of Keytruda monotherapy at a dose of 2 mg/kg every three weeks, which is also the FDA-approved dose for metastatic NSCLC in the United States. Based on this recommendation, a final decision regarding the approval of the therapy is expected from the European Commission in the third-quarter of 2016.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics